Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
leptolide
- Development stage
- Preclinical
- Lead developer
- Consejo Superior de Investigaciones Científicas
- Modality
- Small Molecules
- Administration
- Intraperitoneal
01
Overview
Leptolide is a natural furanocembranolide diterpene originally isolated from the octocorals *Leptogorgia alba* and *Leptogorgia rigida*. Preclinical studies have demonstrated that leptolide acts as an insulin sensitizer, enhancing post-receptor insulin signaling and promoting pancreatic beta-cell proliferation. It has been investigated for its potential therapeutic application in type 2 diabetes mellitus and insulin resistance. Additionally, leptolide exhibits anti-inflammatory and anti-glioinflammatory properties, reducing microglial activation and gliosis in animal models of obesity.
Beyond the preview
Go deeper on leptolide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on leptolide.